# US 2012/0059036 A1 · Method for reducing thrombocytopenia and thrombocytopenia-associated mortality

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0059036 A1
- Document ID: US20120059036A1
- Status: Published application
- Kind: A1
- Application number: 13/130,340
- Filed: 2009-11-20
- Published: 2012-03-08
- Earliest claimed: 2008-11-21
- Inventors: Marco Valgimigli
- Web page: https://patentgrep.com/patent/US20120059036A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/4465: only substituted in position 4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods for reducing the risk of thrombocytopenia-associated mortality and morbidity, and for reducing the risk of becoming thrombocytopenic, in patients whose treatment requires inhibition of platelet aggregation. The methods involve administration of a pharmaceutically acceptable salt of tirofiban.

## Claims

### Claim 1

A method for reducing the risk of thrombocytopenia-associated mortality which comprises administering to a patient suffering from a condition whose treatment requires the inhibition of platelet aggregation a therapeutically effective amount of a pharmaceutically acceptable salt of tirofiban.

### Claim 2

A method for reducing the risk of becoming thrombocytopenic which comprises administering to a patient suffering from a condition whose treatment requires the inhibition of platelet aggregation a therapeutically effective amount of a pharmaceutically acceptable salt of tirofiban.

### Claim 3

A method for reducing the risk of thrombocytopenia-associated morbidity which comprises administering to a patient suffering from a condition whose treatment requires the inhibition of platelet aggregation a therapeutically effective amount of a pharmaceutically acceptable salt of tirofiban.

### Claim 4 (depends on 1, 2, 3)

The method according to any one of claims 1-3, wherein the tirofiban is administered intravenously as a high-dose bolus followed by a continuous infusion over time.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the high-dose bolus is about 25 μg/kg and the continuous infusion is about 0.15 μg/kg/min for about 18-24 hours.

### Claim 6 (depends on 1, 2, 3)

The method according to any one of claims 1-3, wherein tirofiban hydrochloride is administered.

### Claim 7 (depends on 4)

The method according to claim 4, wherein tirofiban hydrochloride is administered.

### Claim 8 (depends on 5)

The method according to claim 5, wherein tirofiban hydrochloride is administered.

### Claim 9 (depends on 1, 3)

The method according to claim 1 or 3, wherein the patient is already thrombocytopenic; prethrombocytopenic or predisposed to thrombocytopenia; or normal in this regard.
